Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04079803 · ClinicalTrials.gov registry record · Phase 2
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
A Phase 2 study, sponsored by Cassava Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT04079803: Completed Phase 2 study, sponsored by Cassava Sciences.
NCT04079803 is a Phase 2 study that has completed, run by Cassava Sciences. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04079803, a Phase 2 study, has completed, sponsored by Cassava Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
Primary Outcome
Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid levels of Amyloid beta42
Interventions
- DRUG Placebo oral tablet
- DRUG Simufilam 100 mg tablet
- DRUG Simufilam 50 mg oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
What the finished NCT04079803 record still lists
NCT04079803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT04079803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04079803 about?
NCT04079803 is a clinical study titled "PTI-125 for Mild-to-moderate Alzheimer's Disease Patients". This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
What is the current status of trial NCT04079803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2019-09-09. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT04079803?
The interventions under investigation include: Placebo oral tablet (DRUG), Simufilam 100 mg tablet (DRUG), Simufilam 50 mg oral tablet (DRUG).
Who is sponsoring clinical trial NCT04079803?
This trial is sponsored by Cassava Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04079803's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI